Skip to main content
Fig. 3 | Molecular Medicine

Fig. 3

From: Therapeutic effects of engineered exosome-based miR-25 and miR-181a treatment in spinocerebellar ataxia type 3 mice by silencing ATXN3

Fig. 3

Exosomal miR-25 and miR-181a significantly improved the motor function. (A) Rotarod test was conducted 2 weeks and 4 weeks after initial tail-vein injection of exosomal miRNAs. The latency to fall time was analyzed. (B, C) Beaming-walking test was conducted 2 weeks and 4 weeks after initial exosomal miRNA treatment. The crossing time and number of foot slips were analyzed. N = 8 in each group. Significant differences were detected between the two exosomal miRNA treated groups and the Control-SCA3 group in the rotarod test and beam-walking test at week 4 (at week 2 and 4 for the foot slip numbers). *<0.05, **<0.01

Back to article page

Molecular Medicine

ISSN: 1528-3658